Immunocore Holdings Operating Income Over Time
| IMCR Stock | USD 33.68 0.75 2.28% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Immunocore Holdings Performance and Immunocore Holdings Correlation. Immunocore | Build AI portfolio with Immunocore Stock |
Can Biotechnology industry sustain growth momentum? Does Immunocore have expansion opportunities? Factors like these will boost the valuation of Immunocore Holdings. Market participants price Immunocore higher when confident in its future expansion prospects. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Immunocore Holdings demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 8.22 | Earnings Share (0.58) | Revenue Per Share | Quarterly Revenue Growth 0.292 | Return On Assets |
Understanding Immunocore Holdings requires distinguishing between market price and book value, where the latter reflects Immunocore's accounting equity. The concept of intrinsic value - what Immunocore Holdings' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Immunocore Holdings' price substantially above or below its fundamental value.
Please note, there is a significant difference between Immunocore Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunocore Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Immunocore Holdings' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Immunocore Holdings and related stocks such as Xeris Pharmaceuticals, Janux Therapeutics, and Vera Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XERS | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (26.6 M) | (59.3 M) | (122.4 M) | (122.4 M) | (115.2 M) | (81.9 M) | (44 M) | (33.6 M) | (30.3 M) | (31.8 M) |
| JANX | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (4.8 M) | (32.9 M) | (67.1 M) | (73 M) | (98.8 M) | (89 M) | (84.5 M) |
| VERA | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (48.1 M) | (34.4 M) | (90.9 M) | (102 M) | (167.2 M) | (150.5 M) | (142.9 M) |
| CLDX | (1.9 M) | (43.4 M) | (58.1 M) | (81.4 M) | (122.4 M) | (129.5 M) | (132.9 M) | (121.5 M) | (156.4 M) | (55 M) | (63.4 M) | (71.2 M) | (115.2 M) | (154.5 M) | (195.1 M) | (175.6 M) | (166.8 M) |
| ABCL | (753 K) | (753 K) | (753 K) | (753 K) | (753 K) | (753 K) | (753 K) | (753 K) | (753 K) | (4.1 M) | 156 M | (4.1 M) | 216.5 M | (237.2 M) | (314.8 M) | (283.3 M) | (269.1 M) |
| SION | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (50.3 M) | (70.6 M) | (63.5 M) | (66.7 M) |
| HRMY | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (145.9 M) | 17 M | 87.5 M | 120.2 M | 192 M | 190.8 M | 219.4 M | 230.4 M |
| BHVN | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (114.5 M) | (218.9 M) | (567.9 M) | (436.1 M) | (885.1 M) | (796.6 M) | (756.8 M) |
| MNKD | (25.2 M) | (140.5 M) | (147 M) | (169.4 M) | (179.6 M) | (344.7 M) | 67.3 M | (108.2 M) | (76.6 M) | (44.6 M) | (47.9 M) | (47 M) | (64.1 M) | 8.7 M | 72.6 M | 83.5 M | 87.6 M |
| NUVB | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (32.1 M) | (43.6 M) | (93.3 M) | (119.7 M) | (99.8 M) | (592.6 M) | (533.4 M) | (506.7 M) |
Immunocore Holdings and related stocks such as Xeris Pharmaceuticals, Janux Therapeutics, and Vera Therapeutics Operating Income description
Operating Income is the amount of profit realized from Immunocore Holdings operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Immunocore Holdings is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Immunocore Holdings | IMCR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 92 Park Drive, |
| Exchange | NASDAQ Exchange |
USD 33.68
Additional Tools for Immunocore Stock Analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.